No Image

[Video Profile] TearLab Corporation

March 29, 2009 bjohnson56 1

Patients who dread traditional blood tests (and the accompanying needles) may one day have reason to rejoice. San Diego device company TearLab is developing a point-of-care diagnostic test that uses tears to identify disease-indicating protein biomarkers.

No Image

[Video Profile] Inovio Biomedical Corporation

March 26, 2009 bjohnson56 0

Solid tumors represent 85 percent of all cancers, creating a huge clinical need for localized, site-specific cancer treatment. Inovio Medical Corporation of San Diego is developing DNA-based vaccines that harness the body’s immune system to prevent and treat chronic diseases such as cancer and HIV.

No Image

[Video Profile] eCardio Diagnostics

March 23, 2009 bjohnson56 0

Identifying a cardiac arrhythmia is an important first step in diagnosing a potentially life-threatening heart condition. Texas-based eCardio Diagnostics, a leading provider of digital holter monitors, seeks to improve the speed and accuracy of this process.

No Image

State of the Art: Anti-Adhesion Barriers

March 23, 2009 bjohnson56 1

Many patients are concerned about the external scars that form following surgical procedures, but a much greater risk can come from internal scarring. Adhesions are a type of post-surgical scar tissue that forms between two internal organs or surfaces that are normally separated.

No Image

Two Studies Show Potential for Treating Drug-Resistant TB

March 19, 2009 bjohnson56 0

Tuberculosis, or TB, is one of the world’s most widespread lethal diseases, killing someone every 20 seconds. An estimated one-third of the world’s population is infected with tuberculosis. Current medications for TB must be taken for six months, but many patients stop before they’ve completed the full course, which has caused drug-resistant strains of TB to develop in recent years. However, two new studies are showing promise in treating this highly infectious disease.

According to Science Daily, the Albert Einstein College of Medicine at Yeshiva University found that a combination of two FDA-approved antibiotics showed potential for treating drug-resistant TB. One of the drugs, clavulanate, inhibits a bacterial enzyme that normally protects TB bacteria from the other antibiotic (meropenem). Clinical trials of the combined treatment are scheduled to take place later this year in South Africa and South Korea.